Becton Dickinson raises earnings guidance as Q2 revenue rises
Updated
Updated · MarketWatch · May 7
Becton Dickinson raises earnings guidance as Q2 revenue rises
10 articles · Updated · MarketWatch · May 7
The medical technology company lifted adjusted EPS guidance to $12.52-$12.72 from $12.35-$12.65 after revenue reached $4.71 billion, topping estimates, while adjusted EPS came in at $2.90.
It posted a net loss of $311 million, or $1.11 a share, versus a $308 million profit a year earlier, despite stronger sales across all three business segments.
Interventional revenue led growth at 7.3%, ahead of medical essentials and connected care, and the company maintained its full-year outlook for at least low-single-digit revenue growth.
BD's revenue is up but its stock is down. Can its strategic overhaul convince skeptical investors?
How will BD’s push into AI and smart devices transform patient care and challenge its MedTech rivals?